Moderna’s shares fell nearly 5% ahead of Thursday’s long holiday weekend, after a Stat report said biotechnology would have to delay the start of its main phase 3 pandemic vaccine trial. Shares fell as much as 10% on Thursday before the end of the day with a 4.9% drop, increasing …
Read More »Moderna’s actions affected by the COVID-19 vax report of delay in the trial, but biotech says the beginning of July is still on the way
